TY  - JOUR
AU  - Pearson, Andrew D J
AU  - Pfister, Stefan
AU  - Baruchel, Andre
AU  - Bourquin, Jean-Pierre
AU  - Casanova, Michela
AU  - Chesler, Louis
AU  - Doz, François
AU  - Eggert, Angelika
AU  - Geoerger, Birgit
AU  - Jones, David
AU  - Kearns, Pamela R
AU  - Molenaar, Jan J
AU  - Morland, Bruce
AU  - Schleiermacher, Gudrun
AU  - Schulte, Johannes
AU  - Vormoor, Josef
AU  - Marshall, Lynley V
AU  - Zwaan, C Michel
AU  - Vassal, Gilles
TI  - From class waivers to precision medicine in paediatric oncology.
JO  - The lancet  / Oncology
VL  - 18
IS  - 7
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2017-01374
SP  - e394 - e404
PY  - 2017
AB  - New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54
LB  - PUB:(DE-HGF)16
C6  - pmid:28677575
DO  - DOI:10.1016/S1470-2045(17)30442-4
UR  - https://inrepo02.dkfz.de/record/125219
ER  -